Gotz U. Grigoleit
Expertise in
4
conditions

Gotz U. Grigoleit

Oberdürrbacher Str. 6, 
Wuerzburg, BY, DE 
Expertise in
4
conditions
Oberdürrbacher Str. 6, 
Wuerzburg, BY, DE 
OverviewLocationsClinical Research

Overview

Gotz Grigoleit practices in Wuerzburg, Germany. Grigoleit is highly rated in 4 conditions, according to our data. Their top areas of expertise are Graft Versus Host Disease (GvHD), Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Chronic Graft Versus Host Disease (cGvHD), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 54 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Oberdürrbacher Str. 6, Wuerzburg, BY 97080, Germany
Other Locations
Oberdürrbacher Street 6, Wuerzburg, BY 97080, Germany
Josef Schneider Str. 11, Wuerzburg, BY 97080, Germany
Josef Schneider Str. 2, Wuerzburg, BY 97080, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
Enrollment Status: Completed
Publish Date: July 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
Enrollment Status: Terminated
Publish Date: December 02, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

54 Total Publications

Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors.
Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors.
Journal: Cancer communications (London, England)
Published: January 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Grigoleit's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile